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Background: No prior study has investigated whether impairment of speciﬁc cognitive functions at
baseline may predict the short-term treatment outcome of electroconvulsive therapy (ECT) in elderly
non-demented patients with major depression (MD).
Methods: This longitudinal cohort study included 65 elderly patients with unipolar or bipolar MD, aged
60–85 years, treated with formula-based ECT. Treatment outcome was assessed using the 17-item Ha-
milton Rating Scale for Depression (HRSD17). Cognitive function at baseline was assessed using nine
neuropsychological tests or subtests measuring information processing speed, verbal learning and
memory, and aspects of executive function.
Results: A poorer performance on the word reading task of the Color Word Interference Test rendered
higher odds of achieving remission during the ECT course (p¼0.021). Remission was deﬁned as an
HRSD17 score of 7 or less. There were no other signiﬁcant associations between the treatment outcome of
ECT and cognitive performance parameters assessed at baseline.
Limitations: The limited number of subjects may have reduced the generalizability of the ﬁndings.
Multiple statistical tests increase the risk for making a type I error.
Conclusions: How well patients perform on neuropsychological tests at baseline is most likely not a
predictor of, or otherwise not signiﬁcantly associated with the treatment outcome of formula-based ECT
in elderly patients with MD.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Late-life depression (LLD) is associated with a high risk for
disability, physical morbidity, and premature death (Erlangsen
et al., 2006; Schulz et al., 2002), which also lead to high levels of
burden on caregivers and health services (Luppa et al., 2013; Zivin
et al., 2013). Antidepressant medication is the ﬁrst choice of
treatment for major depression (MD) among the elderly (American
Psychiatric Association, 2010). However, about two thirds of the
elderly patients included in a meta-analysis of 51 double-blindB.V. This is an open access article u
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(T.M. Bjølseth).randomized controlled trials (RCTs) did not achieve remission after
a single antidepressant trial, whereas 52% were non-responders
(Kok et al., 2012). When strictly deﬁned, remission is a more
clinically relevant and valid end-point than response because it
has stronger implications for good function and prognosis (Rush
et al., 2006). In comparison, 52–55% of the patients treated with
electroconvulsive therapy (ECT) did not meet the criteria for short-
term remission in two recently published studies (Bjølseth et al.,
2014; Oudega et al., 2011). In these trials, formula-based ECT was
administered to clinical samples of elderly patients, referred to in-
ward treatment of MD.
The proportion of elderly depressed patients who do not
achieve remission is a topic of major concern in the ﬁeld of ger-
iatric psychiatry. One question that has been raised is whether
cognitive impairment may predict a poorer treatment outcome.
Research has focused primarily on to what extent core cognitive
deﬁcits in LLD, speciﬁcally slowed information processing and
reduced executive functioning (Butters et al., 2004; Elderkin-nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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sponse to antidepressant drugs (Pimontel et al., 2012).
Similar patterns of results have emerged, indicating that slo-
wed information processing and impairment in aspects of execu-
tive function are predictive of a poorer outcome of antidepressant
treatment (McLennan and Mathias, 2010). However, methodolo-
gical ﬂaws such as small sample sizes, large numbers of statistical
tests, inadequate adjustments for possible confounders, and out-
come measures of questionable validity, give reason to doubt the
generalizability of ﬁndings (Basso et al., 2013).
In contrast to the numerous studies on predictors of response
to antidepressants, little is known about the neurocognitive
characteristics of elderly patients with MD who achieve remission
after ECT and those who do not. Global cognitive function at
baseline, as measured by the Mini Mental State Examination
(MMSE: Engedal et al., 1988; Folstein et al., 1975), has not been
shown to discriminate between remitters and non-remitters
(Hausner et al., 2011; Oudega et al., 2011). Although being widely
used as a test of cognition in ECT research, it provides only an
overall score which cannot be localized to particular cognitive
domains (Dunne and McLoughlin, 2012). Hence, it remains to be
established whether speciﬁc cognitive functions are predictive of
remission after ECT. In case neurocognitive characteristics of ECT
non-remitters can be identiﬁed, such knowledge can lead to better
tailored treatment, thus reducing the risk of exposing patients to
cognitive side-effects to no avail.
Historically, melancholic features and psychomotor retardation
have been considered predictors of a good treatment outcome
after ECT (Rasmussen, 2009). In contrast to older studies that
corroborated this clinical notion (Hickie et al., 1990, 1996), Fink
et al. (2007), in a large trial of patients treated with bitemporal
ECT, showed that those with melancholic features had a sig-
niﬁcantly lower remission rate than those without them. Diver-
ging ﬁndings may have resulted from changes in diagnostic ter-
minology over the decades (Rasmussen, 2007). Hence, information
processing speed may be positively associated with remission after
ECT. Additionally, an observational study of magnetic resonance
imaging and ECT treatment outcome (Oudega et al., 2011) showed
that severely depressed elderly patients without medial temporal
lobe atrophy had a three-fold greater chance of remitting, com-
pared to patients with it. This ﬁnding implies that difﬁculties with
verbal learning and memory, which are mediated by the temporal
lobes, may be associated with poorer improvement after ECT.
Corresponding with the aforementioned studies, we hypothe-
size that elderly depressed patients showing more impairment of
information processing speed, verbal memory, and executive
function before ECT are less likely to improve from depression
after an acute course of ECT, compared to those performing better
on such neuropsychological tests at baseline. To our knowledge, no
study has previously investigated this relationship. To test our
hypothesis, this study was designed to assess whether slower in-
formation processing, deﬁcits in verbal learning and memory, and
lower executive skills were predictive of, or were signiﬁcantly
associated with, a less favorable time trend for symptom severity
when treated with formula-based ECT.2. Methods
2.1. Study design
This longitudinal cohort study originates from a single-site,
assessor-blinded, controlled, parallel-group trial with balanced 1:1
randomization comparing the efﬁcacy of formula-based bifrontal
(BF) vs. right unilateral (RUL) ECT. Because the analyses did not
demonstrate signiﬁcant differences in efﬁcacy between thepatients allocated to BF or RUL electrode placement, the results
will be presented for the participants as one group, consisting of
65 patients. The study is registered at the online clinical trial da-
tabase Clinicaltrials.gov (identiﬁer: NCT01559324). The rando-
mized phase of the study took place between September 1, 2009
and May 1, 2013, and the results of the RCT have recently been
published (Bjølseth et al., 2014).
2.2. Study population
Norwegian-speaking in-hospital patients aged 60–85 years
with a major depressive episode as deﬁned by the DSM-IV-TR
criteria (American Psychiatric Association, 2000), either unipolar
or bipolar, and referred for ECT were eligible for inclusion. Addi-
tional inclusion criteria were a minimum baseline score of 18 on
the 17-item Hamilton Rating Scale for Depression (HRSD17; Ha-
milton, 1960; Williams, 1988) and the ability to co-operate in
testing and to give voluntary informed consent.
Exclusion criteria were an MMSE score of 23 (of 30) or less,
schizophrenia or schizoaffective disorder, serious brain injury (e.g.,
dementia, head injury, or moderate- to large-size stroke), alcohol
or substance abuse in the three weeks prior to ECT, medical con-
ditions contradicting ECT, and having received ECT in the six
months preceding the study.
All patients were recruited from the Department of Geriatric
Psychiatry at the Diakonhjemmet Hospital, a public hospital ser-
ving approximately 230,000 inhabitants of the western and cen-
tral parts of Oslo, of which 28,000 were aged 65 years or older.
2.3. Treatment
2.3.1. Psychotropic medication at baseline
Fifty-six (86.2%) patients had not responded to at least one
adequate trial of an antidepressant prior to admission. For those
individuals, antidepressants were reduced or withdrawn 3–10
days before starting ECT. Forty (61.5%) patients continued receiving
antidepressants at baseline. Thirty-nine (60.0%) were in need of
benzodiazepines for anxiety. The dosages of these drugs were
converted to a deﬁned daily dosage and are listed in Table 1. In 5
(7.7%) patients, anti-epileptic drugs or mood stabilizers were dis-
continued one week prior to ECT. Olanzapin (2.5–20 mg/day) or
quetiapin (50–200 mg/day) were prescribed to 27 (41.5%) patients
with psychotic symptoms or agitation.
2.3.2. ECT
All treatments were administered after hyper-oxygenation for at
least 1 min with 100% oxygen under mask anesthesia with atropine
(0.5–1.0 mg), thiopental (2.5–3.5 mg/kg), and succinylcholine (0.7 mg/
kg), all of which were given intravenously. For ECT using the BF posi-
tion, each electrode was placed 5 cm above the outer angle of the orbit
on a line parallel to the sagittal plane (Letemendia et al., 1993). The
d'Elia placement was used for RUL ECT (D’Elia, 1970). Treatment was
administered twice a week using a Thymatron system IV (Somatics,
LLC, Lake Bluff, Illinois, USA), which delivered a square-wave brief-pulse
(0.5–1.0 ms pulse width) bidirectional current at 0.9 A and 10–70 Hz,
depending on the stimulus intensity. The initial stimulus dose was
determined using the age method (Abrams, 2002) in cases of unilateral
stimulation and the half-age method (Petrides et al., 2009) in cases of
bifrontal stimulation. The dose was adjusted for sex. Women were
administered ﬁve energy percent (25mC) less than the amount de-
rived from the age or half-age formula, and men were administered
ﬁve energy percent more. At subsequent sessions, the stimulus dosage
was adjusted according to the duration, amplitude, and coherence of
electroencephalogram delta waves (American Psychiatric Association,
2001), post-ictal suppression (Azuma et al., 2007), peak post-ictal heart
rate (Swartz, 2002), time to recover orientation (Sobin et al., 1995), and
Table 1
Demographic and clinical characteristics of major depressed elderly patients trea-
ted with electroconvulsive therapy (ECT) (n¼65).
Characteristics Elderly patients with major
depression
(n¼65)
Demographic characteristics
Age, mean (SD), years 74.9 (6.5)
Female, n (%) 36 (55.4)
Years of education, mean (SD) 13.5 (2.9)
Clinical characteristics
Unipolar depression, n (%) 58 (89.2)
Bipolar depression, n (%) 7 (10.8)
Psychotic symptoms, n (%) 15 (23.1)
Melancholic symptoms, n (%) 62 (95.4)
Co-morbid anxiety disorder, n (%) 16 (24.6)
Previous alcohol abuse, n (%) 7 (10.8)
Failed trials of Z2 ADa s of different classes,
n (%)
27 (41.5)
History of ECT, n (%) 21 (32.3)
First episode before the age of 60, n (%) 35 (53.8)
Time since onset of ﬁrst episode (median,
range), months
192 (0–720)
Duration of index episode (median, range),
weeks
24 (3–288)
Total CIRS-Gb score, mean (SD) 6.9 (3.6)
DDDc of antidepressants at baseline (med-
ian, range)
0.5 (0–3.0)
DDD of benzodiazepines at baseline (med-
ian, range)
0.8 (1–1.5)
Neurocognitive characteristics at baseline
Global cognitive function
MMSEd, mean (SD) 27.6 (1.9)
Information processing speed
TMT Ae, mean (SD), s 65.8 (22.7)
CWITf 1, color naming, mean (SD), s 42.9 (11.3)
CWIT 2, word reading, mean (SD), s 28.0 (6.1)
Verbal learning and memory
HVLT-Rg total learning, mean (SD) 20.7 (4.7)
HVLT-R delayed recall, mean (SD) 6.8 (2.9)
Executive function
Tower Test, mean (SD) 12.5 (4.1)
CWIT 3, inhibition, mean (SD), s 104.5 (36.0)
Letter Fluency Test, mean (SD) 35.6 (12.1)
Animal Naming Test, mean (SD) 16.7 (5.1)
Treatment outcome of ECT
HRSD17 score at baseline, mean (SD) 23.4 (4.5)
HRSD17 score after ECT, mean (SD) 9.7 (6.2)
Decline in HRSD17 score, mean (SDh) 13.7 (7.2)
No. of ECT sessions, mean (SD) 9.3 (3.3)
a AD, antidepressant.
b CIRS-G, Cumulative Illness Rating Scale.
c DDD, daily deﬁned dosage.
d MMSE, Mini Mental State Examination.
e TMT A, Trail Making Test A.
f CWIT, Color Word Interference Test.
g HVLT-R, Hopkins Verbal Learning Test – Revised.
h SD not adjusted for intra-correlations due to repeated measurements.
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following day, as assessed by the patient and the ward nurse.
Treatments were continued until the patient achieved remis-
sion or until a plateau in the patient's beneﬁt was reached up to a
maximum of 16 sessions.
2.4. Assessment
2.4.1. Diagnostic procedures
Using all available information from the in-ward observation,the patient interviews, the next of kin, and the referring GP, the
diagnosis of MD according to the DSM-IV-TR criteria was con-
ﬁrmed by consensus between two independent and experienced
senior consultants in geriatric psychiatry. In addition, the diag-
nosis of MD was supported by the Mini-International Neu-
ropsychiatric Interview, speciﬁcally the MINI-Plus (Mordal et al.,
2010; Sheehan et al., 1998), which was also used when screening
for psychiatric co-morbidity. Scoring on the Cumulative Illness
Rating Scale for Geriatric Patients was performed, with the ex-
ception of the psychiatric item (Miller et al., 1992), to document
the overall medical burden.
2.4.2. Evaluation of treatment outcome
Two assessors, a study psychologist and a trained test assistant,
conducted the assessments of depressive symptoms and cognitive
function. The HRSD17 was used to assess the decline in symptom
severity. The ﬁrst assessment of symptom severity was carried out
at baseline, on an average of four days before the ﬁrst ECT treat-
ment. Thereafter, patients were assessed every Wednesday be-
tween every second session and on average four days after the last
ECT treatment. Inter-rater reliability between the study psychol-
ogist and the test assistant was tested and found to be high, with
an intra-class correlation of 0.90 with the HRSD17.
2.4.3. Deﬁnition of treatment outcome and drop-outs
The primary outcome was the longitudinal proﬁle of con-
tinuous HRSD17 scores over the treatment course. Additionally, we
used as a primary outcome, the development of the odds of not
meeting the HRSD17 remission criterion at each visit with respect
to baseline. Remission was deﬁned as an HRSD17 score of 7 or less
(Rush et al., 2006; Zimmerman et al., 2013). Patients who termi-
nated the treatment course prematurely were considered to be
drop-outs and were included in the analyses.
2.4.4. Neurocognitive assessment
Global cognitive function was assessed using a revised version
of the MMSE, and mild cognitive impairment was deﬁned as an
MMSE score of 27 or less (Strobel and Engedal, 2008).
Information processing speed refers to the time used to com-
plete simple psychomotor tasks. It was assessed using the Trail
Making Test Part A (TMT A; Reitan and Wolfson, 1993) and the
Delis Kaplan Executive Function System (D-KEFS) Color Word In-
terference Test, Parts 1 and 2 (CWIT; Delis et al., 2005). In the TMT
A, the patient was asked to draw a line in the right order between
circles enclosing numbers from 1 to 25. In the CWIT Part 1, the
patients had to state the color of 50 small colored squares (red,
blue, and green) as quickly as possible, whereas in the CWIT Part 2,
words were read that denoted the same colors printed in black
ink.
Anterograde memory for verbal material, deﬁned as the ability
to form and store new information, was measured using the ofﬁ-
cial Norwegian research version 3 of the Hopkins Verbal Learning
Test – Revised (HVLT-R; Brandt and Benedict, 2001). In this test, a
list of 12 words was presented orally to the patient. Results from
total recall across three trials and free delayed recall after 20–
25 min were recorded.
The umbrella concept of executive functions encompasses a
variety of cognitive abilities, mediated primarily by the prefrontal
cortex, that allow adaptive and goal-directed behavior, such as
planning, organizing, self-monitoring, response inhibition, and
strategy generation (Miyake et al., 2000). Aspects of executive
function were assessed using the D-KEFS Tower Test, the CWIT
Part 3, the Letter Fluency Test from the D-KEFS battery (FAS; Delis
et al., 2005), and the Animal Naming Test (Borowski et al., 1967).
The Tower Test was used to assess the ability to solve problems
and plan by having the participant move ﬁve disks across three
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CWIT Part 3, used to measure inhibition of an over-learned re-
sponse, the participant was asked to state the color in which color
words were printed. The FAS and the Animal Naming Test were
used to measure the ability to organize thinking (Lezak et al.,
2012). In the FAS, the participant was asked to say words that
begin with F, A, and S within a time limit of 60 s for each letter,
whereas in the Animal Naming Test, the participant was asked to
say as many words as possible that belong to the category of an-
imals within a time limit of 60 s.
Patients were given maximum scores on the TMT A and the
CWIT Part 3 if these tasks were not completed within their time
limits of 95 and 180 s, respectively. These ceiling values were given
to 14 (21.5%) patients for the TMT A and to 5 (7.7%) patients for the
CWIT Part 3.
2.5. Ethics
The study was approved by the Regional Committee for Re-
search Ethics in Norway, including the permission to use ECT in
both moderate and severe MD and as a ﬁrst-line treatment in
selected cases. In the week following admission, eligible patients
and their next of kin were given thorough written and oral in-
formation about ECT, the purpose of the trial, and the procedures
involved. Inclusion was based strictly upon informed consent with
the patient's signature.
2.6. Statistical analyses
Descriptive and outcome analyses were conducted using SPSS
version 22.0 and SAS version 9.3, respectively. Results with p Va-
lues of 0.025 or less were considered statistically signiﬁcant. All
tests were two-sided.
2.6.1. Descriptive analyses
Demographic and clinical characteristics were presented as
means and standard deviations (SDs) for continuous symme-
trically distributed data, whereas skewed data were presented as
medians and ranges. Categorical variables were presented as fre-
quencies and percentages. To explore whether neurocognitive
function was associated with demographic and clinical character-
istics, test scores were compared between males and females,
between those who had and had not previously received ECT, and
between those who were and were not in need of benzodiazepines
at baseline. Comparisons of scores were also performed between
patients who did and did not present with psychotic symptoms,
previous alcohol abuse, early-onset depression, bipolar disorder,
melancholic symptoms, anxiety disorder, and resistance to phar-
macotherapy. These comparisons were performed using either an
independent sample t test or the Mann–Whitney test, as
appropriate.
2.6.2. Missing data
The HRSD17 scores were imputed using inclusion values for
seven patients that lacked baseline data. This was assumed to be
valid because symptom severity did not likely change signiﬁcantly
during the ﬁve days (on average) that passed between inclusion
and baseline assessment. Four patients did not complete either the
TMT A (1), the CWIT Part 1 (2), the CWIT Part 2 (2), the Tower Test
(2), the CWIT Part 3 (2), the Animal Naming Test (1), or the Letter
Fluency Test (2), resulting in 12 (2.1%) missing neurocognitive
values. Because cognitive performance was somewhat more im-
paired in psychotic patients, the missing values were imputed
using the average score from the group that displayed psychotic
symptoms or did not, as appropriate.2.6.3. Outcome analyses
Time-trend in continuous treatment outcome was assessed
using a linear mixed model with ﬁxed effects for ﬁrst-, second-,
and third-order time components and with random effects for
intercepts. A logistic regression model for hierarchical data was
estimated to assess time-trend in dichotomous treatment out-
come. The model contained ﬁxed effects for ﬁrst- and second-or-
der time components and random effects for intercepts. The nine
time-trend models, one for each neurocognitive test used as a
predictor, were estimated for each of the two outcomes. The
models were further adjusted for four a priori chosen covariates,
the presence of psychosis, symptom severity at baseline using the
Montgomery and Aasberg Depression Rating Scale (MADRS;
Montgomery and Aasberg, 1979), time since onset, and polarity.
Each model was reduced by applying Akaike's Information Cri-
terion, where a smaller value represents a better model. The ad-
justment variables were chosen on clinical grounds, and have been
previously shown to correlate with either ECT treatment outcome
or cognitive function. Finally, the reduced models were adjusted
for the confounders, age and years of education. The interactions
between two neuropsychological tests (HVLT-R total learning and
the Tower Test) and psychosis were assessed when estimating the
models, but were not signiﬁcant and therefore excluded.3. Results
3.1. Participant ﬂow
In the original RCT, a total of 79 patients were randomized, and
six had no post-baseline assessments (Bjølseth et al., 2014). An
additional eight patients were excluded from this observational
study because of their inability to co-operate during neu-
ropsychological tests as a result of psychosis (n¼4) or because
they had suffered serious brain injury (n¼4). This yielded a sam-
ple of 65 patients. The inclusion of seven patients who prema-
turely terminated the ECT course did not introduce a bias to the
analysis. Drop-outs, apart from being somewhat older than com-
pleters (80.1 vs. 74.3 years, p¼0.023), did not perform signiﬁcantly
worse on any neuropsychological test.
3.2. Characteristics
Table 1 lists demographic and clinical characteristics of the
sample. Fifteen (23.1%) patients presented with psychotic symp-
toms, and 27 (41.5%) were resistant to pharmacotherapy in that
they failed at least two trials of different-class antidepressants.
Twenty-seven (41.5%) displayed mild cognitive impairment at
baseline. A considerable improvement in cognition was observed
in ﬁfteen (55.6%) of these patients because they no longer met the
criterion for mild cognitive impairment after treatment.
When comparing neuropsychological test results across de-
mographic and clinical categories, no signiﬁcant group differences
were found except in the categories of sex and presence of psy-
chotic symptoms. Female patients had a lower mean score on the
Tower Test (p¼0.024). Delusional patients performed worse than
non-delusional patients on the HVLT-R total learning subtest
(p¼0.014) and the Tower Test (p¼0.012). Hence, post-hoc ana-
lyses were performed to assess whether psychosis had a con-
founding effect on the associations between the results of these
two tests and treatment outcome.
3.3. ECT treatment outcome
The mean (SD) change in HRSD17 scores from baseline to the
end of ECT was 13.7 (7.2) points (Table 1). The trajectories of the
Fig. 1. Trajectories of observed and estimated mean scores for the 17-item Hamilton Rating Scale for Depression (HRSD17) and odds ratios for not meeting the HRSD17
remission criterion during the electroconvulsive therapy course. The number of patients assessed at each time point was: baseline (65) and visits 1 (65), 2 (65), 3 (63), 4 (50),
5 (38), 6 (27), 7 (17), and 8 (6).
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mated odds ratios for not having achieved remission during
treatment are shown in Fig. 1. According to the linear mixed model
for HRSD17, there was a signiﬁcant non-linear downward tendency
during the ECT course (po0.001). Similarly, there was a signiﬁcant
non-linear trend during the ECT course in the development of
odds of not meeting the remission criterion, according to the lo-
gistic regression model for hierarchical data (po0.01). In the
study population, 37 (56.9%) patients did not achieve remission,
whereas 28 (43.1%) did.
3.4. Treatment outcome of ECT in relation to speciﬁc neurocognitive
functions
We assessed the associations between performance on the
neuropsychological tests at baseline and the longitudinal proﬁles
of continuous and dichotomized HRSD17 scores over the ECT
course using a multivariate regression analysis. Adjusting for
covariates and confounders minimally altered the results for the
time components of these proﬁles. Table 2 shows the crude and
adjusted regression coefﬁcients and the odds ratios for the effects
of each test or subtest on the trajectories of estimated HRSD17
mean scores and the odds of not having achieved remission during
treatment (Fig. 1). We found no signiﬁcant association between
performance on any of the neuropsychological tests and treatment
outcome before adjusting for a priori chosen covariates (symptom
severity, psychosis, time since onset, and polarity) and con-
founders (age and years of education). In the ﬁnal model, however,
higher scores on the CWIT Part 2 were signiﬁcantly negatively
associated with the longitudinal proﬁle of the odds of not meeting
the remission criterion, implying that patients with poorer per-
formances on this subtest had higher odds of achieving remission
during the ECT course.
3.5. Post-hoc analyses
We explored whether the presence of psychosis had a con-
founding effect on associations between performance on two tests
(HVLT-R total learning subtest and Tower Test) and treatment
outcome because delusional patients displayed lower mean scores
on those tests compared with non-delusional patients. There wasno signiﬁcant interaction between the presence of psychosis and
test performance in relation to the time-trend for HRSD17 mean
scores or the development of the odds of not meeting the HRSD17
remission criterion. Thus, ECT treatment outcome was predicted
by test performance in a similar way in patients with and without
psychotic symptoms.4. Discussion
To the best of our knowledge, this is the ﬁrst study in-
vestigating whether speciﬁc cognitive functions at baseline are
predictive of the short-term treatment outcome of ECT. Previous
studies have reported major difﬁculties in recruiting frail elderly
depressed patients displaying psychomotor retardation and in-
decisiveness to take part in neuropsychological testing prior to ECT
(Gardner and O’Conn, 2008; O’Connor et al., 2010; Stek et al.,
2007). Thus, the small sample sizes of these studies did not make
it possible to assess the predictive value of test results.
Our data offered no convincing evidence for our hypothesis,
given its power to support it. This result implicates that non-de-
mented elderly patients who present with slower information
processing and deﬁcits in verbal memory and executive function
are as likely to improve from depression after an acute course of
ECT as those performing better on neuropsychological tests at
baseline. When adjustments for possible confounders were made,
a poorer performance on the CWIT Part 2 rendered higher odds of
meeting the remission criterion during the ECT course. This ﬁnd-
ing must be interpreted with caution because there were no sig-
niﬁcant associations between the longitudinal proﬁle of con-
tinuous HRSD17 scores and the results of this subtest or between
treatment outcome and performance on the other tests, used to
measure information processing speed. Moreover, a single statis-
tically signiﬁcant association can be coincidental, because using
multiple statistical tests increases the risk for a type I error.
It has been suggested that elderly depressed patients who re-
ceive ECT and take part in a controlled trial are clinically too
homogenous to be included in a study that aims to examine
whether neurocognitive performance can predict treatment out-
come (Hickie et al., 1996). Such an explanation seems more un-
likely in our study because we included patients with mild
Table 2
Analyses of associations between continuous and dichotomous treatment outcomes of the ECT course, and neuropsychological test results at baseline, in elderly patients
with major depression (n¼65). Models for continuous HRSD17 scores contain time components up to third-order. Models for dichotomized HRSD17 scores contain time
components up to second-order.
Test effect on continuous HRSD17 mean scores
Crude effect Adjusted effect
R.c.a(95% CI)b pb R.c. (95% CI)c pc
Information processing speed
TMT Ad 0.02 (0.03; 0.07) 0.372 0.02 (0.02; 0.06) 0.413
CWITe1, color naming 0,02 (0.12; 0.08) 0.682 0.04 (0.13; 0.04) 0.337
CWIT 2, word reading 0.08 (0.26; 0.10) 0.356 0.09 (0.24; 0.05) 0.204
Verbal learning and memory
HVLT-Rf total learning 0.09 (0.33; 0.14) 0.418 0.05 ( 0.17; 0.26) 0.656
HVLT-R delayed recall 0.27 (0.64; 0.11) 0.164 0.05 (0.38; 0.28) 0.770
Executive function
Tower 0.01 (0.28; 0.26) 0.950 0.02 (0.22; 0.26) 0.863
CWIT 3, inhibition 0.01 (0.02; 0.04) 0.367 0.01 (0.02; 0.03) 0.648
Letter Fluency 0.02 (0.07; 0.11) 0.649 0.03 (0.04; 0.11) 0.366
Animal Naming 0.15 (0.36; 0.07) 0.177 0.12 (0.32; 0.07) 0.214
Test effect on odds ratios for not having met the HRSD17 remission criteriong
Crude effect Adjusted effect
ORh(95% CI) pi OR (95% CI) pj
Information processing speed
TMT A 1.01 (0.98; 1.04) 0.433 1.01 (0.98; 1.03) 0.607
CWIT 1, color naming 0.98 (0.93; 1.03) 0.425 0.97 (0.93; 1.01) 0.143
CWIT 2, word reading 0.96 (0.88; 1.05) 0.369 0.92 (0.86; 0.99) 0.021
Verbal learning and memory
HVLT-R total learning 0.99 (0.88; 1.12) 0.928 1.03 (0.93; 1.15) 0.544
HVLT-R delayed recall 0.89 (0.72; 1.09) 0.248 0.94 (0.80; 1.11) 0.461
Executive function
Tower 1.04 (0.90; 1.20) 0.588 1.02 (0.90; 1.15) 0.761
CWIT 3, inhibition 1.00 (0.98; 1.02) 0.957 1.00 (0.99; 1.01) 0.878
Letter Fluency 1.01 (0.97; 1.07) 0.554 1.03 (0.99; 1.07) 0.125
Animal Naming 0.98 (0.87; 1.11) 0.792 1.00 (0.90; 1.11) 0.960
a R.c., regression coefﬁcient.
b p Value from a bivariate linear mixed model.
c p Value from a multivariate linear mixed model (adjusted for test result, psychosis, symptom severity at baseline, the presence of unipolar and bipolar disorders, age
and years of education).
d TMT A, Trail Making Test A.
e CWIT, Color Word Interference Test.
f HVLT-R, Hopkins Verbal Learning Test – Revised.
g Remission deﬁned as an HRSD17 score of 7 or less.
h OR, odds ratio.
i p Value from a bivariate logistic regression model for hierarchical data.
j p Value from a multivariate logistic model for hierarchical data (adjusted for test result, psychosis, symptom severity at baseline, time since onset, age and years of
education).
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clinical practice. The lack of association between poorer ECT
treatment outcome and slower information processing and more
deﬁcits in verbal memory and executive function, compared to
ﬁndings using antidepressants (Alexopoulos et al., 2005; Mor-
imoto et al., 2011; Potter et al., 2004; Sneed et al., 2007; Story
et al., 2008), can be explained by ECT working better than anti-
depressants in elderly patients with psychomotor retardation,
memory problems, and impaired executive skills. Alternatively, it
may be that the symptom severity in the aforementioned studies
was less grave. Hence, test performance may have been hampered
by inertia, inattentiveness, and lack of motivation to a lesser de-
gree, thus yielding scores that more accurately described the op-
timal cognitive capacity of the patients, compared to the under-
achievement seen among some participants in our study group. At
baseline, indications of mild cognitive impairment were found in
27 (41.5%) patients, whereas 15 (23.1%) were no longer categorized
as impaired after the ECT course. Similarly, a misdiagnosis ofdementia has been reported in elderly patients with MD before
they were successfully treated with ECT (Pier et al., 2012; Wagner
et al., 2011). However, several studies have demonstrated that
despite the improvement observed in some patients after treat-
ment (Dybedal et al., 2015), cognitive functioning remained im-
paired at the group level in elderly depressed patients who pre-
sented with cognitive impairment at baseline (Butters et al., 2000;
Sarapas et al., 2012). Consequently, changes in the intensity of
depressive symptoms appear to have only a small inﬂuence on
cognitive performance.
Inclusion of patients in need of benzodiazepines between ECT
sessions, with anxiety disorders and recent alcohol/substance
abuse rendered our clinical sample representative of an elderly
population normally referred for in-ward treatment for MD in
Norway. Nevertheless, it is likely that such conditions may have
contributed to a relatively low remission rate of 43.1%; remission
rates of 67–90% have been reported in clinical trials that included
more highly selected elderly patients (O’Connor et al., 2001; Tew
T.M. Bjølseth et al. / Journal of Affective Disorders 185 (2015) 67–75 73et al., 1999). In these studies, ECT was administered with stimulus
titration, and remission was deﬁned as an HRSD24 score of 10 or
less among completers. Our relatively low remission rate can also
be explained by the fact that we incorporated the whole sample,
including drop-outs, who met strict remission criteria and that
formula-based ECT provides a suboptimal stimulus dose for el-
derly patients with a high seizure threshold (McCall, 2009; Tiller
and Ingram, 2006).
Moreover, this study did not necessarily refute that the de-
pression executive dysfunction model (Alexopoulos, 2001) is ap-
plicable to ECT because we did not map the extent of white matter
abnormalities in our sample. The model predicts that depressed
patients with impaired executive skills are less likely to respond to
pharmacotherapy, whereas other types of cognitive function are
largely non-related to treatment response. This theory is based on
the premise that disruption of frontal–subcortical neural circuits
contributes both to the development and perpetuation of LLD and
to executive dysfunction. Neither did a meta-analysis of 17 anti-
depressant trials (McLennan and Mathias, 2010) lend strong sup-
port to the model. The authors emphasized that Type I error and
the confounding effects of age and depression severity at baseline
could possibly account for the observed associations between
cognition and response to medication. Therefore, they questioned
the role of neuropsychological tests at baseline in predicting an-
tidepressant outcome in the clinical setting. We share the same
doubt when it comes to ECT. Our ﬁndings indicate that cognitive
performance at baseline does not offer a reliable basis for making
clinical judgments about the likely treatment outcome of formula-
based ECT.5. Limitations
A limited number of subjects may have reduced the general-
izability of our ﬁndings. However, 65 of the 73 participants (89%)
in our original sample took part in neuropsychological testing at
baseline. This yielded a relatively large and representative study
population for non-demented elderly patients with MD receiving
ECT.
Multiple comparisons may have resulted in spurious ﬁndings
(type I error). However, we chose not to adjust p Values other than
for primary outcomes for multiple testing because reducing the
chance of incorrectly producing a difference on an individual test
will increase the chance of falsely retaining the null hypothesis
(type II error) for all tests.
The use of HRSD17 as a primary outcome measure may have led
to an under- or over-estimation of the efﬁcacy of ECT in delusional
patients. The sum of its item scores has recently been found to
have limited validity for assessing the severity and improvement
of psychotic depression (Ostergaard et al., 2014a) because only
delusions and hallucinations with very speciﬁc themes can be
rated. In future research, these shortcomings can be overcome by
using a new composite rating scale, the Psychotic Depression As-
sessment Scale, which has demonstrated good content and clinical
validity (Ostergaard et al., 2014b).
The dual confounding effects of psychosis on both treatment
outcome and neurocognitive predictors may have led to biased
estimates of the associations of interest, because patients with
psychotic symptoms had better odds of achieving remission
(Bjølseth et al., 2014) and because delusional patients performed
worse than non-delusional patients on tests measuring verbal
learning (HVLT-R total learning subtest) and aspects of executive
function (Tower Test). Thus, the negative association between
performance on the CWIT Part 2 word reading task and the odds of
not meeting the remission criterion may have been confounded by
the interaction between psychosis and information processingspeed. However, we found no signiﬁcant interaction between the
presence of psychosis and neuropsychological test results in our
models. Consequently, cognitive performance at baseline pre-
dicted treatment outcome in a similar way in delusional and non-
delusional patients, implying that our estimates of associations
between cognition and ECT treatment outcome were not biased.
As previously discussed, it is unlikely that our primary ﬁnding
was confounded by state effects. To minimize state and treatment
effects on cognitive performance, Simpson et al. (1998) deferred
assessment until six months after the ECT course when in-
vestigating the inﬂuence of cognitive functions on treatment
outcome in LLD. Out of 75 patients aged 65–85 years, 43 (57%)
were treated with ECT or lithium augmentation. The authors did
not ﬁnd signiﬁcant differences in verbal learning, memory, or as-
pects of executive function between ECT/lithium remitters and
non-remitters. Moreover, our aim was not to investigate the as-
sociation between the cognitive capacity of optimally treated el-
derly patients with MD and ECT treatment outcome because
neuropsychological test results at follow-up do not have predictive
value.6. Conclusion
In the context of a relatively small sample of elderly non-de-
mented patients with MD, the treatment outcome of an acute
course of ECT was not predicted by, or otherwise signiﬁcantly as-
sociated with, performance on baseline neuropsychological tests
that measure information processing speed, verbal learning and
memory, and aspects of executive function. One single statistically
signiﬁcant ﬁnding, indicating that poorer performance on the
word reading task of the CWIT rendered higher odds of meeting
the remission criterion during the ECT course, can most probably
be attributed to Type I error. Hence, there is no reason to expect
that non-demented elderly patients with impaired cognitive
function are less likely to improve from depression after ECT,
compared with those who show no cognitive impairment. Further
research is warranted to determine whether ECT works better
than antidepressants in elderly depressed patients who exhibit
psychomotor retardation and deﬁcits in memory and executive
function, as our ﬁndings imply.Role of funding source
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